Validity to the S&N acquisition rumor?

Discussion in 'DePuy Ortho' started by anonymous, Sep 23, 2015 at 9:22 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Just read this morning:

    S&N added 1.8 per cent to £11.65 on talk of interest from Johnson & Johnson, whose DePuy orthopaedic subsidiary was pushed to number three in the market for knee implants byZimmer’s purchase of Biomet.
     

  2. anonymous

    anonymous Guest

    Don't waste time thinking this would ever happen. It would be a no go with FTC . J&J still has a lot to get sorted before going after this deal. The action plan is to get back into the cardiac stent, mapping and ablation arena. They have divested the losing cardiac companies in the MD&D franchise and going to go into this area bigger than ever before with guidant or SJM.

    Q-1. 2016
     
  3. anonymous

    anonymous Guest

    Were you not following strykers look into buying SN. SN really good at fudging numbers, Stryker had a good look and realized the numbers don't add up. The Synthes reps in my territory still trying to carry the joint bag from depuy. Yet there is NO coverage.
     
  4. anonymous

    anonymous Guest

    JnJ has loads of cash but with the constant losing of trauma market share I don't know if Depuy wants another loser
     
  5. anonymous

    anonymous Guest

    that link is 3 months old......things change. #3 in joints is not where they want to be, plus no real products in the pipeline.
     
  6. anonymous

    anonymous Guest

    Smith & Nephew would be a nice buy. Good primary implants, BHR, sports med, wound products also. Why not? Spend the money and just keep getting bigger and better
     
  7. anonymous

    anonymous Guest

    Unfortunately, getting bigger does not equate to getting better
     
  8. anonymous

    anonymous Guest

    BHR....You serious Clark?
     
  9. anonymous

    anonymous Guest

    Which ones???
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest

    Bhr? Haven't had enough hip lawsuits?
     
  12. anonymous

    anonymous Guest

    DePuy folks still act and have conveniently always acted since 2002 as if Oxinium doesn't exist, because DePuy has no comparable product. Ceramic surface doesn't reduce polyethylene wear you say? What is the point in selling Delta alumina femoral heads then?
     
  13. anonymous

    anonymous Guest

    Ceramic head use is growing due to taper corrosion issue with COCR heads, not reduction in poly wear, dumb ass.
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    Well thank you for setting me straight on that issue. Maybe a Charnley would follow with extension of that argument. Why have a separate head and stem at all After all the alumina provides no wear benefit over CoCrMo (?)
     
  16. anonymous

    anonymous Guest


    Inventory issues....I thought we cleared this up a few decades ago
     
  17. anonymous

    anonymous Guest

    You at least think the previous responding rep would concede that Ni ions are no issue with Oxinium. But no, typical DePuy.
     
  18. anonymous

    anonymous Guest

    Most DePuy reps are smart enough to know that ceramic on poly wears less than cobalt chrome on poly. Whether it has clinical significance is still up for debate. Some surgeon use ceramic heads for wear rate and some recently switched due to concerns over fretting.

    Alot of DePuy reps and/or distributors have started working with Aesculap to provide an option for nickel allergy patients. I would rather us buy them than smith and nephew.
     
  19. anonymous

    anonymous Guest